What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Vaccines

PUBLISHER: 360iResearch | PRODUCT CODE: 2166737

PUBLISHER: 360iResearch | PRODUCT CODE: 2166737

Pneumococcal Polysaccharide Vaccine Market - Global Forecast 2026-2032

PUBLISHED: October 29, 2026

PAGES: 195 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Pneumococcal Polysaccharide Vaccine Market is projected to grow by USD 5.30 billion at a CAGR of 9.59% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 2.79 billion
Estimated Year [2026]	USD 3.06 billion
Forecast Year [2032]	USD 5.30 billion
CAGR (%)	9.59%

Pneumococcal Polysaccharide Vaccines: Executive Overview

Pneumococcal polysaccharide vaccines help protect against invasive disease caused by selected serotypes of Streptococcus pneumoniae. Their public-health relevance is linked to severe outcomes such as pneumonia, meningitis, and bloodstream infection, particularly among older adults, people with chronic conditions, and individuals with weakened immunity. Policy decisions increasingly consider polysaccharide vaccines alongside conjugate products, local epidemiology, product indications, and national immunization guidance.

Policy and Delivery Shifts Reshaping Pneumococcal Prevention

The landscape is shifting from product-centered decisions toward life-course immunization strategies. Authorities are refining recommendations by age, risk status, prior vaccination, and available vaccine formulations, while health systems are integrating adult vaccination into primary care, pharmacies, hospitals, and chronic-disease services. Persistent barriers include missed appointments, uneven access, differences in reimbursement, cold-chain requirements, and the need for clearer communication about revaccination and sequential schedules.

How Artificial Intelligence Can Improve Pneumococcal Immunization

Artificial intelligence can support pneumococcal prevention by identifying people who may be eligible from electronic health records, predicting missed vaccinations, and prioritizing outreach to high-risk populations. Natural-language tools can assist clinicians in interpreting complex vaccination histories, while analytics can help programs monitor uptake, safety signals, and geographic gaps. Responsible use requires validated data, transparent clinical oversight, privacy safeguards, and controls against unequal performance across age, ethnicity, socioeconomic status, and health-system settings.

Regional Insights Across Pneumococcal Vaccine Programs

North America generally benefits from established adult-immunization infrastructure, but uptake still depends on provider recommendation, insurance coverage, and coordinated records. Europe combines mature surveillance with varied national schedules, procurement systems, and reimbursement rules. Asia-Pacific spans highly diverse epidemiology and delivery capacity, making integration with primary care and older-adult services important. Latin America continues to balance public-sector access, fiscal constraints, and uneven surveillance. The Middle East shows differing levels of national-program maturity and private-sector participation, while Africa faces substantial burdens from infectious disease, limited health-system capacity, and the need to strengthen routine and adult vaccination platforms.

Group-Level Priorities Across ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN members face diverse financing, surveillance, and delivery environments, creating a need for interoperable guidance and stronger regional procurement coordination. BRICS countries encompass large and heterogeneous populations, so national strategies must address urban-rural disparities and varying adult-immunization capacity. European Union members benefit from shared technical collaboration but retain distinct schedules and reimbursement policies. G7 systems can advance evidence-based adult vaccination, digital registries, and post-market monitoring. GCC countries often have comparatively concentrated health infrastructure and substantial expatriate populations, requiring inclusive access policies. NATO members can incorporate pneumococcal prevention into health-resilience planning, particularly for vulnerable populations and continuity of care.

Country Insights: Diverse National Approaches to Pneumococcal Prevention

Australia uses national immunization guidance and risk-based recommendations to support protection of older adults and medically vulnerable groups. Brazil and Mexico must address regional inequality and differences between public and private delivery. Canada and the United States rely on mature clinical guidance, yet access, documentation, and provider engagement remain important. China and India face substantial population diversity and varied regional health-system capacity, emphasizing surveillance and scalable primary care. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom continue to refine adult and risk-based vaccination pathways within established health systems. Russia's priorities include maintaining access across geographically dispersed populations and strengthening consistent program delivery.

Actions for Leaders to Strengthen Pneumococcal Vaccine Programs

Industry leaders should align evidence generation with national policy questions, including comparative use of vaccine types, sequencing, durability, and protection in high-risk groups. They should simplify eligibility and scheduling messages, support interoperable vaccination records, and work with providers to embed recommendations in routine encounters. Operational priorities include resilient supply planning, temperature-control assurance, pharmacovigilance, and equitable access models. Partnerships with public-health agencies should focus on transparent education, real-world outcomes, and measurable improvements in coverage rather than promotion alone.

Methodology for Assessing the Pneumococcal Polysaccharide Vaccine Landscape

This executive summary uses a structured secondary-research framework focused on authoritative immunization recommendations, public-health surveillance, regulatory information, peer-reviewed clinical evidence, and health-system implementation literature. Findings are synthesized by geography and multilateral group, with attention to disease burden, eligibility guidance, delivery infrastructure, access conditions, and emerging digital capabilities. Because the available reference identifies the market category but provides no quantitative dataset, the assessment intentionally excludes market estimates, market sizing, shares, and forecasts.

Conclusion: Building More Equitable Pneumococcal Protection

Pneumococcal polysaccharide vaccination remains relevant within broader, evidence-based strategies for preventing serious pneumococcal disease. Progress will depend less on product availability alone than on accurate risk identification, consistent recommendations, accessible delivery, reliable records, and sustained public confidence. Regional and country differences require adaptable implementation, while artificial intelligence can add value only when deployed with strong governance, clinical accountability, and equity safeguards.

Product Code: MRR-1F6B5542863C

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pneumococcal Polysaccharide Vaccine Market, by Age Group

7.1. Introduction
7.2. Adults 18-64
- 7.2.1. 18-44
- 7.2.2. 45-64
7.3. Elderly 65+
- 7.3.1. 65-74
- 7.3.2. 75+
7.4. Pediatrics 0-17
- 7.4.1. 0-2
- 7.4.2. 13-17
- 7.4.3. 3-12

8. Pneumococcal Polysaccharide Vaccine Market, by Administration Route

8.1. Introduction
8.2. Intramuscular
8.3. Subcutaneous

9. Pneumococcal Polysaccharide Vaccine Market, by Presentation

9.1. Introduction
9.2. Pre-Filled Syringes
9.3. Vials
- 9.3.1. Multi-Dose Vials
- 9.3.2. Single-Dose Vials

10. Pneumococcal Polysaccharide Vaccine Market, by End User

10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Clinics
- 10.3.1. Government Clinics
- 10.3.2. Private Clinics
10.4. Hospitals
- 10.4.1. Private Hospitals
- 10.4.2. Public Hospitals

11. Pneumococcal Polysaccharide Vaccine Market, by Distribution Channel

11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies

12. Pneumococcal Polysaccharide Vaccine Market, by Region

12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa

13. Pneumococcal Polysaccharide Vaccine Market, by Group

13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO

14. Pneumococcal Polysaccharide Vaccine Market, by Country

14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
- 15.2.1. Concentration Ratio (CR)
- 15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Abbott
16.2. Biological E. Limited
16.3. Cadila Healthcare
16.4. Emergent BioSolutions
16.5. GC Biopharma Corp.
16.6. GlaxoSmithKline
16.7. Merck & Co.
16.8. Panacea Biotec Ltd.
16.9. Pfizer Inc.
16.10. Sanofi
16.11. Seqirus
16.12. Serum Institute of India
16.13. Takeda
16.14. Walvax Biotechnology
16.15. Xiamen Innovax Biotech Co. Ltd.

17. Key Experts